Isogenica, Biolauncher and Cresset Biomolecular Discovery have formed a collaborative joint venture to develop an innovative end-to-end therapeutic discovery platform. The parties will integrate their expertise in peptide library design, evolutionary screening, next generation sequencing, structural analytics and molecular field-based computational chemistry to identify active compounds against high-value therapeutic targets.   The new approach harnesses the vast chemical and conformational dive...